The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
Open accessAbstract
The chemokine stromal cell–derived factor (SDF-1; also known as chemokine ligand 12 [CXCL12]) regulates many essential biological processes, including cardiac and neuronal development, stem cell motility, neovascularization, angiogenesis, apoptosis, and tumorigenesis. It is generally believed that SDF-1 mediates these many disparate processes via a single cell surface receptor known as chemokine receptor 4 (CXCR4). This paper characterizes an alternate receptor, CXCR7, which binds with high affinity to SDF-1 and to a second chemokine, interferon-inducible T cell α chemoattractant (I-TAC; also known as CXCL11). Membrane-associated CXCR7 is expressed on many tumor cell lines, on activated endothelial cells, and on fetal liver cells, but on few other cell types. Unlike many other chemokine receptors, ligand activation of CXCR7 does not cause Ca2+ mobilization or cell migration. However, expression of CXCR7 provides cells with a growth and survival advantage and increased adhesion properties. Consistent with a role for CXCR7 in cell survival and adhesion, a specific, high affinity small molecule antagonist to CXCR7 impedes in vivo tumor growth in animal models, validating this new receptor as a target for development of novel cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor
Feng, Y., Broder, C. C., Kennedy, P. E., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5263.872 · Cited by 4,172
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development
Zou, Y.-R., Kottmann, A. H., Kuroda, M., Taniuchi, I., & Littman, D. R. (1998) · Nature · doi:10.1038/31269 · Cited by 2,489
Self-citationNagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S.-I., Kitamura, Y., Yoshida, N., Kikutani, H., & Kishimoto, T. (1996) · Nature · doi:10.1038/382635a0 · Cited by 2,338
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
Bleul, C. C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski, J., & Springer, T. A. (1996) · Nature · doi:10.1038/382829a0 · Cited by 1,953
Ma, Q., Jones, D., Borghesani, P. R., Segal, R. A., Nagasawa, T., Kishimoto, T., Bronson, R. T., & Springer, T. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9448 · Cited by 1,682
Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J.-L., Arenzana-Seisdedos, F., Schwartz, O., Heard, J.-M., Clark-Lewis, I., Legler, D. F., et al. (1996) · Nature · doi:10.1038/382833a0 · Cited by 1,652
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract
Tachibana, K., Hirota, S., Iizasa, H., Yoshida, H., Kawabata, K., Kataoka, Y., Kitamura, Y., Matsushima, K., Yoshida, N., Nishikawa, S.-I., et al. (1998) · Nature · doi:10.1038/31261 · Cited by 1,525
Loetscher, M., Gerber, B., Loetscher, P., Jones, S. A., Piali, L., Clark-Lewis, I., Baggiolini, M., & Moser, B. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.963 · Cited by 1,193
Cited by
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
“CXCR7, the chemokine receptor for CXCL11, is also expressed on many tumor cells and can transmit growth- and survivalpromoting signals (Burns et al., 2006).”
BackgroundAptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
CXCR3 ligands: redundant, collaborative and antagonistic functions
Groom, J. R., & Luster, A. D. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.158 · Cited by 1,001
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
“In addition, stromal-derived factor 1 (SDF-1 or CXCL12) is considered one of the key regulators of hematopoietic stem and progenitor cell trafficking between the peripheral circulation and targeted tissues.”
BackgroundInfluentialBachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
Sun, X., Cheng, G., Hao, M., Zheng, J., Zhou, X., Zhang, J., Taichman, R. S., Pienta, K. J., & Wang, J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9256-x · Cited by 727
The Intricate Role of CXCR4 in Cancer
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-411638-2.00002-1 · Cited by 672
Chemokines and chemokine receptors: new insights into cancer-related inflammation
Lazennec, G., & Richmond, A. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.003 · Cited by 650
The role of CXC chemokines and their receptors in cancer
Vandercappellen, J., Van Damme, J., & Struyf, S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.050 · Cited by 643
Sierro, F., Biben, C., Martínez-Muñoz, L., Mellado, M., Ransohoff, R. M., Li, M., Woehl, B., Leung, H., Groom, J., Batten, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702229104 · Cited by 624
Control of Chemokine-Guided Cell Migration by Ligand Sequestration
Boldajipour, B., Mahabaleshwar, H., Kardash, E., Reichman-Fried, M., Blaser, H., Minina, S., Wilson, D., Xu, Q., & Raz, E. (2008) · Cell · doi:10.1016/j.cell.2007.12.034 · Cited by 622
CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling
Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F., & Lagane, B. (2009) · Blood · doi:10.1182/blood-2008-12-196618 · Cited by 613
The SDF-1–CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis
Petit, I., Jin, D., & Rafii, S. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.05.007 · Cited by 603
β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7
Rajagopal, S., Kim, J., Ahn, S., Craig, S., Lam, C. M., Gerard, N. P., Gerard, C., & Lefkowitz, R. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912852107 · Cited by 600
Role of chemokines in tumor growth
Raman, D., Baugher, P. J., Thu, Y. M., & Richmond, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.05.013 · Cited by 578
Miao, Z., Luker, K. E., Summers, B. C., Berahovich, R., Bhojani, M. S., Rehemtulla, A., Kleer, C. G., Essner, J. J., Nasevicius, A., Luker, G. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610444104 · Cited by 533
Self-citationThe Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Meads, M. B., Hazlehurst, L. A., & Dalton, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2223 · Cited by 520
Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.001 · Cited by 485
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T., Ghobrial, J. M., Jia, X., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035857 · Cited by 478
CXCR7 Functions as a Scavenger for CXCL12 and CXCL11
Naumann, U., Cameroni, E., Pruenster, M., Mahabaleshwar, H., Raz, E., Zerwes, H.-G., Rot, A., & Thelen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009175 · Cited by 470
Inflammation-induced DNA damage, mutations and cancer
Kay, J., Thadhani, E., Samson, L., & Engelward, B. (2019) · DNA Repair · doi:10.1016/j.dnarep.2019.102673 · Cited by 464
The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer
Wang, J., Shiozawa, Y., Wang, J., Wang, Y., Jung, Y., Pienta, K. J., Mehra, R., Loberg, R., & Taichman, R. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707465200 · Cited by 457
Self-citationRetractedMatrix metalloproteinases in inflammation
Nissinen, L., & Kähäri, V.-M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.03.007 · Cited by 444
CXCR4 is required for the quiescence of primitive hematopoietic cells
Nie, Y., Han, Y.-C., & Zou, Y.-R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072513 · Cited by 407
Immune regulation by atypical chemokine receptors
Nibbs, R. J. B., & Graham, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3544 · Cited by 407
The chemokine system in cancer biology and therapy
Mantovani, A., Savino, B., Locati, M., Zammataro, L., Allavena, P., & Bonecchi, R. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.007 · Cited by 393
The unique structural and functional features of CXCL12
Janssens, R., Struyf, S., & Proost, P. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.107 · Cited by 378
Chemokines and Chemokine Receptors: Standing at the Crossroads of Immunobiology and Neurobiology
Ransohoff, R. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.010 · Cited by 371
Chemokines in health and disease
Raman, D., Sobolik-Delmaire, T., & Richmond, A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.01.005 · Cited by 366
LI, M., & RANSOHOFF, R. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.11.003 · Cited by 352
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
Ghysen, A., & Dambly-Chaudière, C. (2007) · Genes & Development · doi:10.1101/gad.1568407 · Cited by 340
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
Shi, Y., Riese, D. J., & Shen, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574667 · Cited by 336
CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration
Décaillot, F. M., Kazmi, M. A., Lin, Y., Ray-Saha, S., Sakmar, T. P., & Sachdev, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277038 · Cited by 333
Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S., & Proost, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01970 · Cited by 328
Davenport, A. P., Alexander, S. P. H., Sharman, J. L., Pawson, A. J., Benson, H. E., Monaghan, A. E., Liew, W. C., Mpamhanga, C. P., Bonner, T. I., Neubig, R. R., et al. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007179 · Cited by 327
The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression
Sánchez-Martín, L., Estecha, A., Samaniego, R., Sánchez-Ramón, S., Vega, M. Á., & Sánchez-Mateos, P. (2011) · Blood · doi:10.1182/blood-2009-12-258186 · Cited by 325
How chemokines invite leukocytes to dance
Thelen, M., & Stein, J. V. (2008) · Nature Immunology · doi:10.1038/ni.f.207 · Cited by 324
Microfluidic Endothelium for Studying the Intravascular Adhesion of Metastatic Breast Cancer Cells
Song, J. W., Cavnar, S. P., Walker, A. C., Luker, K. E., Gupta, M., Tung, Y.-C., Luker, G. D., & Takayama, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005756 · Cited by 317
Valentin, G., Haas, P., & Gilmour, D. (2007) · Current Biology · doi:10.1016/j.cub.2007.05.020 · Cited by 310
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties
Kalatskaya, I., Berchiche, Y. A., Gravel, S., Limberg, B. J., Rosenbaum, J. S., & Heveker, N. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.053389 · Cited by 309
Dambly-Chaudière, C., Cubedo, N., & Ghysen, A. (2007) · BMC Developmental Biology · doi:10.1186/1471-213x-7-23 · Cited by 297
O'Hayre, M., Salanga, C. L., Handel, T. M., & Allen, S. J. (2008) · Biochemical Journal · doi:10.1042/bj20071493 · Cited by 297
Hattermann, K., Held-Feindt, J., Lucius, R., Müerköster, S. S., Penfold, M. E. T., Schall, T. J., & Mentlein, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3642 · Cited by 295
Self-citationZabel, B. A., Wang, Y., Lewén, S., Berahovich, R. D., Penfold, M. E. T., Zhang, P., Powers, J., Summers, B. C., Miao, Z., Zhao, B., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900269 · Cited by 294
Self-citationCxcr7 controls neuronal migration by regulating chemokine responsiveness
Sánchez-Alcañiz, J. A., Haege, S., Mueller, W., Pla, R., Mackay, F., Schulz, S., López-Bendito, G., Stumm, R., & Marín, O. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.006 · Cited by 290
“This view was challenged with the discovery that the orphan receptor RDC1, now designated as Cxcr7, is also able to bind Cxcl12 (Balabanian et al., 2005a; Burns et al., 2006).”
BackgroundInfluentialThe CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease
Döring, Y., Pawig, L., Weber, C., & Noels, H. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00212 · Cited by 289
Enhancing the Migration Ability of Mesenchymal Stromal Cells by Targeting the SDF-1/CXCR4 Axis
Marquez-Curtis, L. A., & Janowska-Wieczorek, A. (2013) · BioMed Research International · doi:10.1155/2013/561098 · Cited by 287
How chemokines organize the tumour microenvironment
Mempel, T. R., Lill, J. K., & Altenburger, L. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00635-w · Cited by 281
Korbecki, J., Kojder, K., Kapczuk, P., Kupnicka, P., Gawrońska-Szklarz, B., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020843 · Cited by 273
Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine
Lau, T. T., & Wang, D.-A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.546338 · Cited by 270
CXCL12-CXCR4 Engagement Is Required for Migration of Cutaneous Dendritic Cells
Kabashima, K., Shiraishi, N., Sugita, K., Mori, T., Onoue, A., Kobayashi, M., Sakabe, J.-I., Yoshiki, R., Tamamura, H., Fujii, N., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070225 · Cited by 268
Zheng, H., Fu, G., Dai, T., & Huang, H. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318093ec8f · Cited by 267
Klos, A., Wende, E., Wareham, K. J., & Monk, P. N. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005223 · Cited by 264
Organ selectivity in metastasis: regulation by chemokines and their receptors
Ben-Baruch, A. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9097-3 · Cited by 264
Mazzinghi, B., Ronconi, E., Lazzeri, E., Sagrinati, C., Ballerini, L., Angelotti, M. L., Parente, E., Mancina, R., Netti, G. S., Becherucci, F., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071903 · Cited by 264
CXC Chemokines in Cancer Angiogenesis and Metastases
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06003-3 · Cited by 263
Role of Chemokines in Endocrine Autoimmune Diseases
Rotondi, M., Chiovato, L., Romagnani, S., Serio, M., & Romagnani, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0044 · Cited by 257
Müller, N., Michen, S., Tietze, S., Töpfer, K., Schulte, A., Lamszus, K., Schmitz, M., Schackert, G., Pastan, I., & Temme, A. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000082 · Cited by 253
The blood-brain barrier, chemokines and multiple sclerosis
Holman, D. W., Klein, R. S., & Ransohoff, R. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.019 · Cited by 247
“Until recently it was believed that CXCL12 mediated its effects exclusively via interactions with CXCR4, however the receptor CXCR7, formerly the orphan receptor RDC1, has now been shown to bind CXCL12 as well as CXCL11 [135,136].”
BackgroundCruz-Orengo, L., Holman, D. W., Dorsey, D., Zhou, L., Zhang, P., Wright, M., McCandless, E. E., Patel, J. R., Luker, G. D., Littman, D. R., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102010 · Cited by 231
Self-citationSchönemeier, B., Kolodziej, A., Schulz, S., Jacobs, S., Hoellt, V., & Stumm, R. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21780 · Cited by 141
Tarnowski, M., Grymula, K., Liu, R., Tarnowska, J., Drukala, J., Ratajczak, J., Mitchell, R. A., Ratajczak, M. Z., & Kucia, M. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0288 · Cited by 136
Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair
Li, M., Hale, J. S., Rich, J. N., Ransohoff, R. M., & Lathia, J. D. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.06.003 · Cited by 104
CXCL12/CXCR4 signalling in neuronal cell migration
Tiveron, M.-C., & Cremer, H. (2008) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2008.06.004 · Cited by 98
Honoki, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1220 · Cited by 90
Downregulation of CXCL12 in mesenchymal stromal cells by TGFβ promotes breast cancer metastasis
Yu, P. F., Huang, Y., Xu, C. L., Lin, L. Y., Han, Y. Y., Sun, W. H., Hu, G. H., Rabson, A. B., Wang, Y., & Shi, Y. F. (2017) · Oncogene · doi:10.1038/onc.2016.252 · Cited by 88
Self-citationSupport of Tumor Endothelial Cells by Chemokine Receptors
Salazar, N., & Zabel, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00147 · Cited by 72
MIF and CXCL12 in Cardiovascular Diseases: Functional Differences and Similarities
van der Vorst, E. P. C., Döring, Y., & Weber, C. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00373 · Cited by 57
Role of chemokines and chemokine receptors in prostate cancer development and progression.
Singh, R. K., Sudhakar, A., & Lokeshwar, B. L. (2010) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000030 · Cited by 45
Aydoğdu, N., Rudat, C., Trowe, M.-O., Kaiser, M., Lüdtke, T. H., Taketo, M. M., Christoffels, V. M., Moon, A., & Kispert, A. (2018) · Development · doi:10.1242/dev.171827 · Cited by 41
RhoH plays distinct roles in T-cell migrations induced by different doses of SDF1α
Wang, H., Zeng, X., Fan, Z., & Lim, B. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.02.005 · Cited by 16
Metadata
- Authors
- Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M. E. T., Sunshine, M. J., Littman, D. R., Kuo, C. J., Wei, K., McMaster, B. E., Wright, K., Howard, M. C., & Schall, T. J.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-08-28
- Volume
- 203
- Issue
- 9
- Pages
- 2201-2213
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2171581347
- Cited by
- 1,263
- References
- 32
- FWCI
- 31.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.